Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine

Neurotoxicology and Teratology

Volumn 54, Issue , 2016, Pages 5-14

  Deshmukh, Uma ^a,e   Adams, Jane ^c   Macklin, Eric A ^a,b   Dhillon, Ruby ^a   McCarthy, Katherine D ^a   Dworetzky, Barbara ^b,d   Klein, Autumn ^b,d   Holmes, Lewis B ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic; Behavior; Carbamazepine; Lamotrigine; Pregnancy; Valproate

Indexed keywords

ALCOHOL; CARBAMAZEPINE; FOLIC ACID; LAMOTRIGINE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADAPTIVE BEHAVIOR; ARTICLE; BIRTH WEIGHT; CHILD; CHILD BEHAVIOR; COMMUNICATION DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DISEASE REGISTRY; DOSE RESPONSE; EDUCATION; EPILEPSY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEARING DISORDER; HUMAN; INTERPERSONAL COMMUNICATION; MATERNAL AGE; MEMORY DISORDER; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PRENATAL EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPENSITY SCORE; PSYCHOMETRY; REGRESSION ANALYSIS; SCORING SYSTEM; SEIZURE; SMOKING; SOCIAL PROBLEM; SOCIALIZATION; STATISTICAL SIGNIFICANCE; TELEPHONE; TREND STUDY; VINELAND II ADAPTIVE BEHAVIOR SCALE; ADAPTATION SYNDROME; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED; DEVELOPMENTAL DISABILITIES; MALE; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PSYCHOLOGY;

ANALYSIS OF VARIANCE; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; EPILEPSY; FEMALE; GENERAL ADAPTATION SYNDROME; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; TRIAZINES; VALPROIC ACID;

EID: 84956655812     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2016.01.001     Document Type: Article

References (47)

1. Adab N., Jacoby A., Smith D., Chadwick D. Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 2001, 70:15-21.
2. Adab N., Kini U., Vinten J., Ayres J., Baker G., Clayton-Smith J., Coyle H., Fryer A., Gorry J., Gregg J., Mawer G., Nicolaides P., Pickering L., Tunnicliffe L., Chadwick D.W. The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 2004, 75:1575-1583.
3. Alsdorf R., Wyszynski D.F. Teratogenicity of sodium valproate. Expert Opin. Drug Saf. 2005, 4:345-353.
4. American Psychiatric A, American Psychiatric A, Force DSMT Diagnostic and statistical manual of mental disorders: DSM-5 2013.
5. Ardinger H.H., Atkin J.F., Blackston R.D., Elsas L.J., Clarren S.K., Livingstone S., Flannery D.B., Pellock J.M., Harrod M.J., Lammer E.J., et al. Verification of the fetal valproate syndrome phenotype. Am. J. Med. Genet. 1988, 29:171-185.
6. Artama M., Auvinen A., Raudaskoski T., Isojarvi I., Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 64:1874-1878.
7. Baker G.A., Bromley R.L., Briggs M., Cheyne C.P., Cohen M.J., Garcia-Finana M., Gummery A., Kneen R., Loring D.W., Mawer G., Meador K.J., Shallcross R., Clayton-Smith J., Liverpool, Manchester Neurodevelopment G IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015, 84:382-390.
8. Bromley R.L., Mawer G., Clayton-Smith J., Baker G.A., Liverpool, Manchester Neurodevelopment G Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008, 71:1923-1924.
9. Bromley R.L., Mawer G.E., Briggs M., Cheyne C., Clayton-Smith J., Garcia-Finana M., Kneen R., Lucas S.B., Shallcross R., Baker G.A., Liverpool, Manchester Neurodevelopment G The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psychiatry 2013, 84:637-643.
10. Campbell E., Kennedy F., Russell A., Smithson W.H., Parsons L., Morrison P.J., Liggan B., Irwin B., Delanty N., Hunt S.J., Craig J., Morrow J. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J. Neurol. Neurosurg. Psychiatry 2014, 85:1029-1034.
11. Christensen J., Gronborg T.K., Sorensen M.J., Schendel D., Parner E.T., Pedersen L.H., Vestergaard M. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
12. Cohen M.J., Meador K.J., Browning N., Baker G.A., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav. 2011, 22:240-246.
13. Cohen M.J., Meador K.J., Browning N., May R., Baker G.A., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W., Group NS Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013, 29:308-315.
14. Cummings C., Stewart M., Stevenson M., Morrow J., Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch. Dis. Child. 2011, 96:643-647.
15. Dar S., Lazer T., Swanson S., Silverman J., Wasser C., Moskovtsev S.I., Sojecki A., Librach C.L. Assisted reproduction involving gestational surrogacy: an analysis of the medical, psychosocial and legal issues: experience from a large surrogacy program. Hum. Reprod. 2015, 30:345-352.
16. Dean J.C., Hailey H., Moore S.J., Lloyd D.J., Turnpenny P.D., Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet. 2002, 39:251-259.
17. Eriksson K., Viinikainen K., Monkkonen A., Aikia M., Nieminen P., Heinonen S., Kalviainen R. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res. 2005, 65:189-200.
18. Gaily E., Kantola-Sorsa E., Hiilesmaa V., Isoaho M., Matila R., Kotila M., Nylund T., Bardy A., Kaaja E., Granstrom M.L. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004, 62:28-32.
19. Holmes L.B., Mittendorf R., Shen A., Smith C.R., Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch. Neurol. 2011, 68:1275-1281.
20. Kanne S.M., Gerber A.J., Quirmbach L.M., Sparrow S.S., Cicchetti D.V., Saulnier C.A. The role of adaptive behavior in autism spectrum disorders: implications for functional outcome. J. Autism Dev. Disord. 2011, 41:1007-1018.
21. Klin A., Saulnier C.A., Sparrow S.S., Cicchetti D.V., Volkmar F.R., Lord C. Social and communication abilities and disabilities in higher functioning individuals with autism spectrum disorders: the Vineland and the ADOS. J. Autism Dev. Disord. 2007, 37:748-759.
22. Mandell D.S., Novak M.M., Zubritsky C.D. Factors associated with age of diagnosis among children with autism spectrum disorders. Pediatrics 2005, 116:1480-1486.
23. Mawer G., Clayton-Smith J., Coyle H., Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002, 11:512-518.
24. Meador K.J., Baker G.A., Finnell R.H., Kalayjian L.A., Liporace J.D., Loring D.W., Mawer G., Pennell P.B., Smith J.C., Wolff M.C., Group NS In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006, 67:407-412.
25. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W., Group NS Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 2009, 360:1597-1605.
26. Meador K.J., Baker G.A., Browning N., Cohen M.J., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W., Group NS Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404.
27. Meador K.J., Baker G.A., Browning N., Cohen M.J., Bromley R.L., Clayton-Smith J., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W., Group NS Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013, 12:244-252.
28. Moore S.J., Turnpenny P., Quinn A., Glover S., Lloyd D.J., Montgomery T., Dean J.C. A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. 2000, 37:489-497.
29. Morrow J., Russell A., Guthrie E., Parsons L., Robertson I., Waddell R., Irwin B., McGivern R.C., Morrison P.J., Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 2006, 77:193-198.
30. Nadebaum C., Anderson V.A., Vajda F., Reutens D.C., Barton S., Wood A.G. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011, 76:719-726.
31. Omtzigt J.G., Los F.J., Grobbee D.E., Pijpers L., Jahoda M.G., Brandenburg H., Stewart P.A., Gaillard H.L., Sachs E.S., Wladimiroff J.W., et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992, 42:119-125.
32. Rasalam A.D., Hailey H., Williams J.H., Moore S.J., Turnpenny P.D., Lloyd D.J., Dean J.C. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev. Med. Child Neurol. 2005, 47:551-555.
33. Samren E.B., van Duijn C.M., Koch S., Hiilesmaa V.K., Klepel H., Bardy A.H., Mannagetta G.B., Deichl A.W., Gaily E., Granstrom M.L., Meinardi H., Grobbee D.E., Hofman A., Janz D., Lindhout D. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
34. Samren E.B., van Duijn C.M., Christiaens G.C., Hofman A., Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 1999, 46:739-746.
35. Scolnik D., Nulman I., Rovet J., Gladstone D., Czuchta D., Gardner H.A., Gladstone R., Ashby P., Weksberg R., Einarson T., et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994, 271:767-770.
36. Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A., Liverpool Manchester Neurodevelopment G., Epilepsy U.K., Pregnancy R. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76:383-389.
37. Sparrow S.S., Balla D.A., Cicchetti D.V., Doll E.A. Vineland-II: Vineland adaptive behavior scales: survey forms manual 2005, AGS Publishing, Circle Pines, Minn.
38. Thomas S.V., Ajaykumar B., Sindhu K., Nair M.K., George B., Sarma P.S. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008, 13:229-236.
39. Titze K., Koch S., Helge H., Lehmkuhl U., Rauh H., Steinhausen H.C. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev. Med. Child Neurol. 2008, 50:117-122.
40. Tomson T., et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015, 56(7):1006-1019. (Jul, Epub 2015 May 16). 10.1111/epi.13021.
41. Vajda F.J., Hitchcock A., Graham J., Solinas C., O'Brien T.J., Lander C.M., Eadie M.J. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur. J. Neurol. 2006, 13:645-654.
42. Veiby G., Daltveit A.K., Schjolberg S., Stoltenberg C., Oyen A.S., Vollset S.E., Engelsen B.A., Gilhus N.E. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 2013, 54:1462-1472.
43. Viinikainen K., Eriksson K., Monkkonen A., Aikia M., Nieminen P., Heinonen S., Kalviainen R. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006, 9:636-640.
44. Vinten J., Adab N., Kini U., Gorry J., Gregg J., Baker G.A., Liverpool, Manchester Neurodevelopment Study G Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005, 64:949-954.
45. Vinten J., Bromley R.L., Taylor J., Adab N., Kini U., Baker G.A., Liverpool, Manchester Neurodevelopment G The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009, 14:197-201.
46. Wide K., Winbladh B., Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. 2004, 93:174-176.
47. Wyszynski D.F., Nambisan M., Surve T., Alsdorf R.M., Smith C.R., Holmes L.B., Antiepileptic Drug Pregnancy R Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965.